These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9049656)

  • 1. Locoregional IL-2 immunotherapy of bladder cancer.
    Santoni A; Velotti F; Giuffrida A; Santoni G; Piccoli M
    Immunopharmacol Immunotoxicol; 1997 Feb; 19(1):1-13. PubMed ID: 9049656
    [No Abstract]   [Full Text] [Related]  

  • 2. New approaches to intravesical chemo-immunotherapy in superficial bladder cancer.
    van der Meijden AP
    Prog Clin Biol Res; 1992; 378():95-101. PubMed ID: 1301591
    [No Abstract]   [Full Text] [Related]  

  • 3. [Specific medicinal treatment of bladder cancers].
    Schneider M; Thyss A; Caldani C; Lesbats G
    Bull Soc Sci Med Grand Duche Luxemb; 1984; 121(1):27-35. PubMed ID: 6541101
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravesical therapy: does it affect the natural history of superficial bladder cancer?
    Lamm DL; Griffith JG
    Semin Urol; 1992 Feb; 10(1):39-44. PubMed ID: 1565903
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapeutic agents: intravesical instillation.
    Brixey MT
    Urol Nurs; 1988; 9(2):4-6. PubMed ID: 3145560
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study.
    Ferlazzo G; Magno C; Iemmo R; Rizzo M; Lupo G; Semino C; Bruno S; Melioli G
    Anticancer Res; 1996; 16(2):979-80. PubMed ID: 8687163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical role of interleukin-2 in the surgical treatment of liver metastasis due to colon adenocarcinoma].
    Brivio F; Fumagalli L; Fattori L; Nespoli L; Denova M; Sargenti E; Nespoli A
    Minerva Chir; 2004 Dec; 59(6):573-82. PubMed ID: 15876991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
    Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
    Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT; Soloway MS
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superficial bladder cancer--treatment approach.
    Abi-Aad A; Biquet P; Penders L
    Acta Urol Belg; 1996 May; 64(2):19-24. PubMed ID: 8701801
    [No Abstract]   [Full Text] [Related]  

  • 12. Eradication of palpable intradermal murine bladder tumors by systemic interleukin-2 and cyclophosphamide in C3H mice.
    Lee K; O'Donnell RW; Marquis D; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):32-42. PubMed ID: 3286824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
    Velotti F; Tubaro A; Stoppacciaro A; Pettinato A; Morrone S; Bossola P; Napolitano T; Miano L; Ruco L; Piccoli M
    Ann Ist Super Sanita; 1990; 26(3-4):411-21. PubMed ID: 2091503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses?
    Lamm DL; van der Meijden AP; Akaza H; Brendler C; Hedlund PO; Mizutani Y; Ratliff TL; Robinson MR; Shinka T
    Int J Urol; 1995 Jun; 2 Suppl 2():23-35. PubMed ID: 7553302
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Medical treatment of urothelial tumors of the bladder].
    Ferrière JP; Dionet C; Dauplat J; Boiteux JP; Plagne R; Giraud B
    Ann Urol (Paris); 1988; 22(4):229-34. PubMed ID: 3056230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.
    Hendricksen K; Witjes JA
    Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
    Huben RP
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical instillation of interleukin-2. An effective method for preventing the recurrence of bladder cancer.
    Jin F; Yu M
    Chin Med J (Engl); 1995 May; 108(5):373-6. PubMed ID: 7555241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.